| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
* Division of Immunology, Infection, and Inflammation and
Centre for Rheumatic Diseases, Royal Infirmary, University of Glasgow, Glasgow, United Kingdom
Rheumatoid arthritis is characterized by chronic inflammatory infiltration of the synovium, leading to eventual cartilage and bone destruction. Previously, we have reported that soluble T1/ST2 (sST2), a member of the IL-1R gene family, inhibits LPS-induced macrophage proinflammatory cytokine production. In this study, we report the therapeutic effect of sST2-Fc in the murine model of collagen-induced arthritis. A short term administration of sST2-Fc fusion protein significantly attenuated disease severity compared with controls treated with normal IgG. Histological examination revealed that while control IgG-treated mice developed severe cellular infiltration in the joints, synovial hyperplasia, and joint erosion, this pathology was profoundly reduced in sST2-Fc-treated animals. Treatment of sST2-Fc also down-regulated serum levels of IL-6, IL-12, and TNF-
. Spleen cells from the sST2-Fc-treated mice produced significantly less IFN-
, TNF-, IL-6, and IL-12 compared with cells from the control mice when cultured with collagen in vitro. Finally, pretreatment with ST2-Fc markedly inhibited the ability of human monocytic THP1 cells to release TNF- when cocultured with peripheral blood T cells from rheumatoid patients. Together these results demonstrate that sST2-Fc may provide a novel approach in treating chronic autoimmune conditions by inhibiting the release of proinflammatory cytokines.
This article has been cited by other articles:
|
|
 |
|
  Q. Espinassous, E. Garcia-de-Paco, I. Garcia-Verdugo, M. Synguelakis, S. von Aulock, J.-M. Sallenave, A. N. J. McKenzie, and J. Kanellopoulos IL-33 Enhances Lipopolysaccharide-Induced Inflammatory Cytokine Production from Mouse Macrophages by Regulating Lipopolysaccharide Receptor Complex J. Immunol., July 15, 2009; 183(2): 1446 - 1455. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Mato, M. Fujii, Y. Hakamata, E. Kobayashi, A. Sato, M. Hayakawa, H. Ohto-Ozaki, M. Bando, S. Ohno, S. Tominaga, et al. Interleukin-1 receptor-related protein ST2 suppresses the initial stage of bleomycin-induced lung injury Eur. Respir. J., June 1, 2009; 33(6): 1415 - 1428. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Diez Serum Soluble ST2 as a Biochemical Marker of Acute Heart Failure: Future Areas of Research J. Am. Coll. Cardiol., October 28, 2008; 52(18): 1466 - 1467. [Full Text] [PDF]
|
|
|
|
 |
|
 W. A. Verri Jr., A. T. G. Guerrero, S. Y. Fukada, D. A. Valerio, T. M. Cunha, D. Xu, S. H. Ferreira, F. Y. Liew, and F. Q. Cunha IL-33 mediates antigen-induced cutaneous and articular hypernociception in mice PNAS, February 19, 2008; 105(7): 2723 - 2728. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Niedbala, B. Cai, H. Liu, N. Pitman, L. Chang, and F. Y. Liew Nitric oxide induces CD4+CD25+ Foxp3 regulatory T cells from CD4+CD25 T cells via p53, IL-2, and OX40 PNAS, September 25, 2007; 104(39): 15478 - 15483. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. A. Chackerian, E. R. Oldham, E. E. Murphy, J. Schmitz, S. Pflanz, and R. A. Kastelein IL-1 Receptor Accessory Protein and ST2 Comprise the IL-33 Receptor Complex J. Immunol., August 15, 2007; 179(4): 2551 - 2555. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Amatucci, T. Novobrantseva, K. Gilbride, M. Brickelmaier, P. Hochman, and A. Ibraghimov Recombinant ST2 boosts hepatic Th2 response in vivo J. Leukoc. Biol., July 1, 2007; 82(1): 124 - 132. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. T. Fagundes, F. A. Amaral, A. L. S. Souza, A. T. Vieira, D. Xu, F. Y. Liew, D. G. Souza, and M. M. Teixeira ST2, an IL-1R family member, attenuates inflammation and lethality after intestinal ischemia and reperfusion J. Leukoc. Biol., February 1, 2007; 81(2): 492 - 499. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
